Source - SMW
Manuel Llobet, CEO and Nick Wykeman, FD of Allergy Therapeutics (AGY) (LSE:AGY) will be giving a briefing at the Shares Investor Evening on 27th September 2016. It will take place in London at an investor evening being organised by Shares magazine; the event is supported by AJ Bell Youinvest. 

Allergy Therapeutics provides information to healthcare professionals about the prevention, diagnosis and treatment of allergic conditions with a special focus on allergy vaccination (also known as specific immunotherapy or desensitisation therapy). Allergy vaccination is a successful treatment that deals with the underlying cause of allergies and not just the symptoms! Allergy Therapeutics has a long-term commitment to the development of innovative therapies for allergy treatment and allergy prevention.

The Shares event offers a unique opportunity to hear about the latest plans and strategy from the Directors of UK listed companies and Fund Managers, attendees can personally put forward questions to the presenters. The event will take place at the Novotel Tower Bridge, 10 Pepys Street, London EC3N 2NR. Registration begins at 17:15 and presentations at 17.45, followed by a drinks reception where attendees can mingle with the speakers and fellow investors.

Companies presenting at the event include:

Allergy Therapeutics (AGY)


Central Asia Metals (CAML)

MaxCyte (MXCT)

Palace Capital (PCA)

Real Good Food (RGD)

Investors can register now for free at: 

At 3:29pm: (LON:AGY) Allergy Therapeutics PLC share price was 0p at 18.88p

Related Charts

Allergy Therapeutics (AGY)

-1.25p (-4.85%)
delayed 18:15PM